Khosla Impact

Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

HealthifyMe is a fitness application designed to help users achieve their health and weight loss objectives through their computers and smartphones. Launched in 2012 by a team of doctors, nutritionists, and fitness trainers in Bangalore, India, the app allows users to track their calorie intake, monitor nutrition and fitness activities, and assess their weight to determine overall health. With features that enable users to set and work towards healthy goals, the platform also facilitates data sharing with experts, who provide personalized advice and recommendations. The application is enhanced by an artificial intelligence-powered fitness coach that leverages automated analytics, making it easier for users to receive tailored online fitness consultations and achieve their health aspirations.

Even is a health tech company that collaborates with leading hospitals to provide comprehensive healthcare services through a subscription model. Its offerings include unlimited diagnostics, consultations, and hospitalization coverage valued at up to 50 lakh. The company simplifies the reimbursement process by directly transferring funds to partner hospitals, ensuring a seamless experience for members. By charging a recurring monthly fee, Even aims to address critical long-term health needs for individuals, making healthcare more accessible and manageable.

Synex Medical specializes in non-invasive blood testing technology, focusing on the development of a portable device that enables users to monitor metabolite concentrations without penetrating the skin. Utilizing a miniaturized magnetic resonance system, the company can accurately detect critical blood metabolites such as glucose, lactate, and ketones. This innovative approach employs only magnets and radio waves, ensuring there are no adverse health effects associated with its use. By providing precise information about metabolic health, Synex Medical aims to empower individuals to take proactive steps in managing their health and well-being.

Neurode is focused on the development of a non-invasive wearable headset aimed at enhancing cognitive performance for individuals with neurological conditions, particularly ADHD. This innovative device employs electrical stimulation to address the imbalances in brain activity commonly associated with ADHD. Alongside the headset, Neurode offers a companion application that monitors users' progress and shares improvements with healthcare professionals. This drug-free approach seeks to alleviate symptoms such as working memory deficits, attention challenges, and impulse control issues, ultimately enabling better management of cognitive performance for users.

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

Even is a health tech company that collaborates with leading hospitals to provide comprehensive healthcare services through a subscription model. Its offerings include unlimited diagnostics, consultations, and hospitalization coverage valued at up to 50 lakh. The company simplifies the reimbursement process by directly transferring funds to partner hospitals, ensuring a seamless experience for members. By charging a recurring monthly fee, Even aims to address critical long-term health needs for individuals, making healthcare more accessible and manageable.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Limbic is a London-based company that specializes in mental healthcare technology. Founded in 2017, it develops a software development kit (SDK) that leverages machine learning to analyze heart rate data collected from wearable devices like the Apple Watch, allowing for the assessment of users' emotional states. Limbic also offers psychological therapies for adults, focusing on improving mental health through innovative solutions. Its platform supports healthcare professionals by providing tools for stress detection and facilitating clinical assessments, thereby enhancing the efficacy of psychological therapy. By combining AI technology with wearable devices, Limbic aims to address the growing challenges in mental health care and improve patient outcomes.

Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

HealthifyMe is a fitness application designed to help users achieve their health and weight loss objectives through their computers and smartphones. Launched in 2012 by a team of doctors, nutritionists, and fitness trainers in Bangalore, India, the app allows users to track their calorie intake, monitor nutrition and fitness activities, and assess their weight to determine overall health. With features that enable users to set and work towards healthy goals, the platform also facilitates data sharing with experts, who provide personalized advice and recommendations. The application is enhanced by an artificial intelligence-powered fitness coach that leverages automated analytics, making it easier for users to receive tailored online fitness consultations and achieve their health aspirations.

Gather Health is an international healthcare technology company dedicated to empowering patients with chronic diseases to enhance their health. The company specializes in mobile and cloud-based healthcare applications that utilize the latest medical and behavioral change research to motivate and educate patients. By connecting physicians, patients, their families, and patient communities, Gather Health aims to provide continuous and holistic care, ultimately improving health outcomes. The rise in chronic diseases, such as obesity and diabetes, has created a demand for better care, which Gather Health addresses by equipping patients and healthcare providers with effective tools for managing these conditions. Their flagship product, the Gather Health Diabetes platform, has been successfully implemented in cities including Mumbai, Ahmedabad, Hyderabad, Chennai, and Bangalore, showing positive health outcomes for patients and increased efficiency for healthcare providers. Headquartered in Hong Kong, with offices in Beijing, New York, and India, Gather Health's team comprises clinicians, health experts, interaction designers, and engineers experienced in global healthcare.

Synchron is a medical technology company focused on developing innovative brain-computer interface solutions. It manufactures an implantable device known as the stentrode, which is delivered to the brain via a catheter. This minimally invasive device is embedded with electrode arrays that can interpret neuronal signals and modulate neural activity in targeted areas. By enabling patients with motor impairments to control digital devices, prosthetics, and other assistive technologies through thought, Synchron aims to enhance the quality of life for individuals with disabilities.

Even is a health tech company that collaborates with leading hospitals to provide comprehensive healthcare services through a subscription model. Its offerings include unlimited diagnostics, consultations, and hospitalization coverage valued at up to 50 lakh. The company simplifies the reimbursement process by directly transferring funds to partner hospitals, ensuring a seamless experience for members. By charging a recurring monthly fee, Even aims to address critical long-term health needs for individuals, making healthcare more accessible and manageable.

Carver Biosciences is a biotechnology firm specializing in the development of CRISPR/Cas13-based antiviral therapies. The company focuses on creating gene therapies that target RNA viruses, particularly respiratory viruses, at the RNA level. By utilizing the Cas13 technology, Carver aims to destroy these viruses and inhibit their replication. This approach is intended to complement existing vaccination efforts and viral inhibitors, providing patients with alternative treatment options to halt the progression of infections.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.

COR helps you implement globally-proven healthy lifestyle practices, then shows you a totally new type of data about how your body responds. Optimize your lifestyle and discover the impact of different daily customs with precise, science-based self-knowledge.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.

Loop Health is a healthcare provider based in Pune, India, founded in 2018. The company offers a range of services including acute and urgent care, chronic condition management, women's health, health coaching, and preventive care. Loop Health aims to simplify the healthcare experience by connecting patients with family physicians, specialists, and hospitals, facilitating access to major medical treatments. Their team of Loop Coordinators assists patients in finding appropriate doctors, comparing treatment costs, obtaining second opinions, and managing admission procedures, thereby alleviating the stress associated with healthcare decisions. Additionally, Loop Health features a virtual medical practice that supports employees and their families, allowing them to consult with healthcare experts and medical advisors without delay, ultimately promoting better health management and cost-effectiveness.

House Rx is a health technology platform focused on improving affordability and patient access to specialty medications.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Even is a health tech company that collaborates with leading hospitals to provide comprehensive healthcare services through a subscription model. Its offerings include unlimited diagnostics, consultations, and hospitalization coverage valued at up to 50 lakh. The company simplifies the reimbursement process by directly transferring funds to partner hospitals, ensuring a seamless experience for members. By charging a recurring monthly fee, Even aims to address critical long-term health needs for individuals, making healthcare more accessible and manageable.

HealthifyMe is a fitness application designed to help users achieve their health and weight loss objectives through their computers and smartphones. Launched in 2012 by a team of doctors, nutritionists, and fitness trainers in Bangalore, India, the app allows users to track their calorie intake, monitor nutrition and fitness activities, and assess their weight to determine overall health. With features that enable users to set and work towards healthy goals, the platform also facilitates data sharing with experts, who provide personalized advice and recommendations. The application is enhanced by an artificial intelligence-powered fitness coach that leverages automated analytics, making it easier for users to receive tailored online fitness consultations and achieve their health aspirations.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Ellipsis Health, Inc. is a technology company based in San Francisco, California, founded in 2013. It specializes in developing analytics solutions that utilize artificial intelligence to enhance behavioral health assessments by analyzing patient speech and clinical data. The company's platform offers a behavioral biomarker technology that generates clinical-grade evaluations of anxiety and depression severity, as well as sub-clinical assessments of stress. This innovative approach allows healthcare systems to continuously monitor their patient populations for mental health conditions, particularly depression, and facilitates timely support for patients in need. By integrating affective computing into patient and care team interactions, Ellipsis Health aims to create real-time behavioral health vital signs for improved patient outcomes.

Synchron is a medical technology company focused on developing innovative brain-computer interface solutions. It manufactures an implantable device known as the stentrode, which is delivered to the brain via a catheter. This minimally invasive device is embedded with electrode arrays that can interpret neuronal signals and modulate neural activity in targeted areas. By enabling patients with motor impairments to control digital devices, prosthetics, and other assistive technologies through thought, Synchron aims to enhance the quality of life for individuals with disabilities.

Rightway is a technology and services company focused on simplifying healthcare for clients and their members. The company develops care navigation and pharmacy benefit management (PBM) solutions aimed at reducing healthcare spending by guiding members toward optimal care and therapies. Rightway's mission centers on using guidance and advocacy to lower costs and improve healthcare outcomes by aligning incentive models and integrating clinicians into the care journey. Its modern care navigation technology offers clinical guidance at a lower cost compared to traditional solutions. Additionally, Rightway's innovative PBM model ensures that every prescription is directed towards the lowest net cost, thereby minimizing expenses for members. The company’s transparent approach to pharmacy benefits is unique in that it incorporates care navigation, enhancing the overall member experience and engagement while addressing total cost-of-care.

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.

AliveCor, Inc. specializes in developing digital medical-grade electrocardiograms, enabling users to monitor their heart health through mobile technology. The company's flagship product, KardiaMobile, is a personal mobile EKG device that provides instant detection of common heart arrhythmias, along with features for blood pressure and weight tracking, as well as storage for recorded EKGs. Additionally, AliveCor offers KardiaMobile 6L, a six-lead EKG device that allows patients to share detailed EKG readings with healthcare providers. The company also operates KardiaCare, a digital health subscription service that empowers users to manage their heart health conveniently at home. Founded in 2010 and incorporated in 2011, AliveCor is headquartered in Mountain View, California, and is recognized for its innovative contributions to cardiac care through the integration of machine learning techniques.

SiPhox Health, based in Cambridge, Massachusetts, specializes in designing and manufacturing innovative diagnostic solutions. The company develops next-generation diagnostics infrastructure, including at-home test kits and central lab systems. Their flagship product is a disposable biosensor cartridge that assesses 17 blood biomarkers, providing insights into inflammation, hormonal health, metabolic fitness, and cardiovascular health. SiPhox Health's platform merges biochemistry, photonic chip technology, integrated photonics, electronics, and microfluidics to enable sensitive readouts of immunoassays and nucleic acid tests, facilitating point-of-need and at-home diagnostics.

Oobli specializes in the development of healthy, protein-based sweeteners sourced from exotic plants. These unique compounds offer a flavorful experience without the calories typically associated with sugar, making them a suitable alternative for health-conscious consumers. The protein sweeteners are produced through fermentation, ensuring they have no glycemic impact and do not disrupt the gut microbiome. Oobli has successfully obtained regulatory approvals, including FDA "no questions" letters and GRAS status for several of its proteins, reinforcing their commitment to safety and quality. By providing a delicious and low-calorie option, Oobli aims to transform the way individuals approach sweeteners, allowing for healthier choices in everyday consumption.

Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.

Yes Health Inc. is a California-based company that specializes in mobile health solutions, focusing on diabetes prevention and management. Founded in 2015, it offers a comprehensive application that provides personalized nutrition and fitness advice, as well as support from health coaches. The program is designed to engage users actively, making it accessible and effective for individuals looking to adopt healthier lifestyles and prevent the onset of diabetes. Yes Health's team comprises physicians, health coaches, and engineers who work together to create a program that is both affordable and easy to follow. In addition to prevention, the application also aids individuals already diagnosed with diabetes in managing their symptoms effectively, with the overarching mission of promoting lasting health habits and reducing the impact of diabetes.

Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.

E25Bio Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing rapid diagnostic tests for epidemic fever viruses, including dengue, chikungunya, and Zika. Founded in 2018, the company specializes in paper-based diagnostic systems that enable swift detection of viral antigens produced during infections. Its innovative platform allows for real-time data reporting through a mobile application, which captures results along with information on test timing and location. This approach aims to facilitate epidemiologic predictions and disease mapping, ultimately assisting governments and health organizations in managing outbreaks effectively and preventing public health crises. E25Bio's solutions are designed to provide affordable and timely diagnostics at the point of care.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Fountain Therapeutics, Inc. is a biotechnology company focused on developing treatments for age-related diseases. Founded in 2018 and based in San Francisco, California, the company aims to create a future where individuals live healthier for longer. It employs a transformative cellular model that mimics the complex characteristics of aging within a laboratory setting. By integrating this model with advanced artificial intelligence and computer vision, Fountain Therapeutics seeks to establish an innovative platform for identifying novel therapeutic targets. This approach is designed to facilitate the development of effective treatments for diseases associated with aging, ultimately aiming to reverse cellular aging and improve health outcomes.

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Tempo designs and develops a home fitness platform with personal guidance to help users in their training sessions. It features live elite trainers who can help users when they make mistakes. It has built-in three-dimensional sensors that track form, counts reps, and recommend weights. It helps users to improve in real-time. Powered by 3D motion sensors and AI, it analyzes 25 of the body’s essential joints as users work out and gives understood form feedback. Moawia Eldeeb and Joshua Augustin founded it as Pivot in 2015, with its headquarters in San Francisco in California.

Neurotrack Technologies, Inc., established in 2012 and headquartered in Redwood City, California, specializes in digital health solutions for early detection and ongoing monitoring of cognitive impairment, particularly Alzheimer's and other dementias. The company offers a computer-based cognitive test, validated clinically and guided by patients, which can be administered in clinics or at home, fitting various workflows. Neurotrack's proprietary technology has been recognized with 11 patents and is registered as an FDA Class II medical device. The company has published 27 peer-reviewed papers, demonstrating its commitment to scientific rigor and innovation in transforming dementia diagnosis and management.

Future, established in 2017 and headquartered in San Francisco, specializes in personalized online fitness coaching. The company offers one-on-one digital training sessions tailored to clients' needs, whether they're at home, in the gym, or on-the-go. Future's team of coaches comprises experienced professionals who have trained athletes, celebrities, and working individuals alike.

Sword Health is a digital health company specializing in physical rehabilitation. It employs artificial intelligence to deliver personalized care to patients worldwide, anytime, anywhere. The platform offers interactive exercise routines supervised by remote physiotherapists, aiming to reduce costs and improve accessibility to physical therapy. Clinicians can utilize the data collected to enhance decision-making processes.

Cellino is focused on creating an automated biomanufacturing system for personalized cell therapies, with the aim of making these treatments widely accessible. The company leverages an AI-guided laser editing platform that employs image-guided machine learning and robotics to generate autologous induced pluripotent stem cells (iPSCs) at scale. This innovative approach is designed to facilitate the development of potentially curative therapies for chronic degenerative diseases, such as vision loss and Parkinson's disease. By streamlining the process of cell therapy production, Cellino aims to enhance the availability of life-saving medicines for patients around the world.

Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.

Carrot Inc. is a company based in Redwood City, California, that specializes in smoking cessation through its application, Pivot. Founded in 2015, Carrot offers a unique six-stage program that engages smokers early in their journey without imposing pressure to quit. The program begins by fostering awareness of smoking habits and enhancing confidence in the smoker's ability to change. For those who choose to pursue cessation, Pivot assists users in creating and implementing a personalized quit plan, supported by one-on-one coaching until they achieve stability in their quit journey. This approach emphasizes self-motivation and personal commitment, distinguishing Carrot's service in the field of smoking cessation.

Higia Technologies, founded in 2016 and based in Mexico City, develops EVA, a wearable device aimed at assessing breast cancer risk. This non-invasive device features tactile sensors that map the breast's surface and surrounding areas, enabling women to monitor changes in breast temperature, size, and weight. Equipped with biosensors, EVA continuously tracks relevant information, providing users with accessible tools for breast health management.

Nebula Genomics is a company that focuses on human genome sequencing and health data, aiming to create a comprehensive online marketplace for genomic information. Founded in 2016 by Harvard genomics pioneer George Church and his colleagues, the company is headquartered in San Francisco, California, with additional offices in Boston, Massachusetts. Nebula Genomics utilizes blockchain technology to empower consumers by allowing them to maintain control over their genomic data and receive compensation for its use. The platform aggregates extensive genetic information, enabling researchers to analyze data for accelerated drug development and personalized medicine. The company’s DNA sequencing technology covers all genes, regulatory regions, the Y chromosome, and mitochondrial DNA, facilitating in-depth genetic analysis and variant exploration.

Remedy is a prescriptive chronic care analytics platform employing artificial intelligence to help value-based health systems determine who should get what care, when, how, and by whom to maximize patient health outcomes per dollar spent. We are a design-driven company with core medical AI technology capable of diagnosing disease, catching hidden high-risk diagnoses, and projecting the development of patient’s health into the future. Built around our core AI engine, our first product Remedy Sentinel helps value-based providers identify hidden chronic, co-morbid conditions and intervene by engaging high-risk patients prior to onset. We envision a world where healthcare marries the science of “health” with the art of “care”: scientific, data-driven decision making drives the best outcomes for each individual patient, and frees providers to focus on applying their human touch. Remedy combines novel artificial intelligence algorithms for predictive medical analytics with a healthcare-optimized product development process to give leaders the tools they need to transform their delivery networks and thrive in a value-based care environment. With this approach, Remedy builds a scalable suite of products that, when deployed, learn from experience, and grow into a solution optimized to fit the needs of specific provider groups and the populations they serve. Remedy systematically maximizes the patient health outcome achieved with each dollar spent by using AI to help determine what care is delivered to whom, when it is delivered, where it is delivered, how it is delivered, followed, and supported, and who should deliver it. We not only surface insights, but also build the necessary tools and helps coordinate step-by-step implementation processes to affect real change.

Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.

Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

Curai Health is a virtual care company founded in 2017 by Neal Khosla and Xavier Amatriain, headquartered in Palo Alto. The company leverages artificial intelligence to provide chat-based primary care services, aiming to make high-quality and affordable healthcare accessible to everyone, anytime. Curai Health's platform integrates clinicians with advanced AI and machine learning tools to create a learning healthcare system that enhances the efficiency and cost-effectiveness of medical care. By facilitating better communication between patients and healthcare professionals, the platform aids in accurate diagnosis and treatment. Curai Health offers its services directly to consumers and through partnerships with enterprises.

Future, established in 2017 and headquartered in San Francisco, specializes in personalized online fitness coaching. The company offers one-on-one digital training sessions tailored to clients' needs, whether they're at home, in the gym, or on-the-go. Future's team of coaches comprises experienced professionals who have trained athletes, celebrities, and working individuals alike.

Siren Care, Inc. is a health technology company based in San Francisco, California, founded in 2015. It specializes in wearable devices designed for diabetic health tracking, particularly through its flagship product, the Siren diabetic socks. These smart socks continuously monitor foot temperature, providing crucial data that can help detect early signs of diabetic ulcers, thereby reducing the risk of amputations. The temperature data is transmitted via an application, allowing healthcare providers to monitor patients effectively and intervene early if necessary. Siren Care aims to enhance healthcare for individuals with chronic diseases by collaborating with both providers and payers to improve patient outcomes in diabetic foot care.

Neurotrack Technologies, Inc., established in 2012 and headquartered in Redwood City, California, specializes in digital health solutions for early detection and ongoing monitoring of cognitive impairment, particularly Alzheimer's and other dementias. The company offers a computer-based cognitive test, validated clinically and guided by patients, which can be administered in clinics or at home, fitting various workflows. Neurotrack's proprietary technology has been recognized with 11 patents and is registered as an FDA Class II medical device. The company has published 27 peer-reviewed papers, demonstrating its commitment to scientific rigor and innovation in transforming dementia diagnosis and management.

Atomwise, Inc. is a biotechnology company based in San Francisco that specializes in using deep learning artificial intelligence for small molecule drug discovery. Founded in 2012, Atomwise developed the AtomNet platform, which enables virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical approach that leverages experimental affinity measurements and protein structures. The company focuses on addressing over 600 unique disease targets and has established partnerships with more than 250 organizations, including pharmaceutical and biotechnology firms. Atomwise's technology has been recognized for its ability to unlock previously undruggable targets, and the company has raised significant funding to support its mission of accelerating drug discovery and development.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

DiscernDx is a healthcare technology company based in Palo Alto, California, founded in 2017. It operates an online platform that provides users with access to individualized clinical and molecular data, enabling proactive health management and informed decision-making. The platform leverages artificial intelligence and machine learning to detect, measure, and interpret signals from the body, facilitating early disease detection and personalized care. By focusing on the earliest indicators of developing diseases as well as existing conditions, DiscernDx aims to improve health outcomes and transform the healthcare experience for individuals.

Q Bio, Inc., established in 2015, develops a comprehensive health assessment platform that combines advanced non-invasive imaging, genetic testing, vital signs, and medical history to provide a snapshot of an individual's health. The company's flagship product, Q BioVault, aggregates and summarizes an individual's entire medical history, identifying and tracking significant health changes. Q Bio's interdisciplinary team, based in San Carlos, California, comprises experts in fields such as applied math, computational physics, electrical engineering, genetics, and radiology. Backed by prominent venture capital firms, the company aims to empower healthcare professionals with proactive, data-driven insights to improve patient outcomes.

Ellipsis Health, Inc. is a technology company based in San Francisco, California, founded in 2013. It specializes in developing analytics solutions that utilize artificial intelligence to enhance behavioral health assessments by analyzing patient speech and clinical data. The company's platform offers a behavioral biomarker technology that generates clinical-grade evaluations of anxiety and depression severity, as well as sub-clinical assessments of stress. This innovative approach allows healthcare systems to continuously monitor their patient populations for mental health conditions, particularly depression, and facilitates timely support for patients in need. By integrating affective computing into patient and care team interactions, Ellipsis Health aims to create real-time behavioral health vital signs for improved patient outcomes.

Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.

Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.

Karius, Inc. is a life sciences company based in Redwood City, California, specializing in genomic insights for infectious diseases. The company offers a non-invasive blood test known as the Karius Test, which utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. By mapping the microbial landscape of each patient from a single blood draw, Karius aims to assist clinicians in making rapid and informed treatment decisions. The company's laboratory is CLIA-certified and CAP-accredited, ensuring high standards in clinical laboratory testing. Additionally, Karius provides laboratory services for pathogen biomarker detection tailored to biopharmaceutical companies.

Twine Health, Inc. is a healthcare technology company that specializes in a cloud-based platform aimed at chronic disease management. The platform facilitates collaborative care by integrating tools for shared decision-making, self-tracking, and communication between patients and their healthcare providers. Patients can co-create personalized care plans with their care teams, which may include physicians, nurses, family members, and health coaches. This collaborative approach is designed to enhance patient engagement and self-efficacy, ultimately leading to better health outcomes and reduced healthcare costs. Established in 2012 and based in Cambridge, Massachusetts, Twine Health was developed at the MIT Medical Lab and operates as a subsidiary of Fitbit, Inc. since 2018.

Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.

Ontera Inc. specializes in the development of innovative single molecule detection and genome analysis platforms utilizing biochemistry and silicon nanopore chip technology. The company offers a range of products, including the SAM device, which facilitates the detection and quantification of various targets such as acids, proteins, and small molecules across different applications in plants, animals, and humans. Additionally, Ontera provides the DUO Nano platform for genome mapping, structural variant analysis, epigenetics, and direct strand sequencing. Its solutions cater to diverse sectors, including agriculture, human and animal diagnostics, law enforcement, and drug discovery, among others. Founded in 2011 and headquartered in Santa Cruz, California, Ontera was previously known as Two Pore Guys, Inc. before rebranding in May 2019. The company aims to enhance point-of-care testing and advance the field of third-generation sequencing.

Syllable is a technology company that develops a platform designed to enhance communication between patients and healthcare providers through text and voice interactions. The platform enables patients to access vital healthcare information regarding primary care, specialty referrals, vaccinations, and general practice, facilitating guidance outside of traditional clinical settings. Additionally, Syllable focuses on building AI agents and managing AI operations, integrating tools and services from third-party providers of large language models and AI technologies, which further supports its mission to improve patient-provider communication.

Inflammatix, Inc. is a molecular diagnostics company based in Burlingame, California, founded in 2016. The company specializes in developing rapid tests that assess the immune system to address significant clinical and public health challenges. Its primary focus is on creating diagnostics for acute bacterial and viral infections, as well as sepsis, utilizing patent-pending biomarkers exclusively licensed from Stanford University. Inflammatix employs proprietary machine-learning algorithms to analyze immune responses, producing clinically actionable results that support healthcare providers, particularly in emergency medicine, in making informed diagnostic decisions. Additionally, the company is building a diagnostics pipeline that includes tests for tropical infections, autoimmune diseases, transplant rejection, and various other conditions.

Medisas, Inc. offers a cloud-based service that facilitates the transfer of medical information among healthcare professionals during shift changes. Based in the United States, the company develops record-keeping software aimed at improving patient care and safety. This software allows clinicians to document and share critical information related to shift changes, patient transfers, and discharges across various devices. By streamlining communication among healthcare providers, Medisas enhances organizational efficiency and supports better patient outcomes throughout the care process. The team comprises experienced clinicians, engineers, and designers dedicated to transforming hospital software to meet the evolving needs of healthcare organizations.

Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.

Luminostics, Inc. is a healthcare technology company based in Houston, Texas, established in 2015. The company has developed a smartphone-based adaptor that enables users to conduct molecular-level health assessments through do-it-yourself disease testing. This innovative solution allows healthcare professionals and consumers to obtain health information quickly, with tests that can be completed in just 15 minutes. By combining mobile technology with accessible testing methods, Luminostics aims to enhance the way individuals monitor and manage their health.

Lumiata Inc. specializes in predictive health analytics tailored for risk-bearing organizations, including hospital networks and insurance carriers. Founded in 2013 and based in San Mateo, California, the company has developed a medical graph that organizes and analyzes diverse healthcare data, enabling real-time predictive analytics. Its flagship product, The Lumiata Risk Matrix, provides personalized predictions regarding individual health changes, supported by a chain of medical reasoning. By leveraging over 120 million patient records and proprietary clinical knowledge, Lumiata's machine learning tools empower healthcare providers and payers to enhance decision-making, manage costs, and improve patient care. The company serves a range of clients, including payers, population health organizations, and digital health companies, facilitating applications in underwriting and care management while prioritizing member privacy.

Forward is a startup focused on transforming healthcare delivery by incorporating advanced technologies that have been underutilized in the industry, such as sensors, mobile applications, and artificial intelligence. Founded in January 2016 by former executives from Google and Uber, Forward operates primary care clinics that emphasize personalized patient care. Through its mobile application and natural language processing system, the company enhances healthcare services, offering features like body scanning, genetic screening, real-time blood testing, and home monitoring of vital signs. These innovations empower patients to take control of their health, promote transparency, and foster better collaboration with their primary care physicians. Backed by prominent investors and entrepreneurs, Forward aims to redefine the patient experience in healthcare.

Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

Luminist, Inc., based in Newark, California, specializes in developing a diagnostic platform aimed at the early detection and diagnosis of liver disease. Incorporated in 2015, the company focuses on transforming biochemical data into crucial health information, allowing patients to receive insights regarding multiple diseases, including screening for cancer, through a single test. As of April 2020, Luminist operates as a subsidiary of DiscernDx, reinforcing its commitment to advancing healthcare through innovative diagnostic solutions.

Neurotrack Technologies, Inc., established in 2012 and headquartered in Redwood City, California, specializes in digital health solutions for early detection and ongoing monitoring of cognitive impairment, particularly Alzheimer's and other dementias. The company offers a computer-based cognitive test, validated clinically and guided by patients, which can be administered in clinics or at home, fitting various workflows. Neurotrack's proprietary technology has been recognized with 11 patents and is registered as an FDA Class II medical device. The company has published 27 peer-reviewed papers, demonstrating its commitment to scientific rigor and innovation in transforming dementia diagnosis and management.

Twine Health, Inc. is a healthcare technology company that specializes in a cloud-based platform aimed at chronic disease management. The platform facilitates collaborative care by integrating tools for shared decision-making, self-tracking, and communication between patients and their healthcare providers. Patients can co-create personalized care plans with their care teams, which may include physicians, nurses, family members, and health coaches. This collaborative approach is designed to enhance patient engagement and self-efficacy, ultimately leading to better health outcomes and reduced healthcare costs. Established in 2012 and based in Cambridge, Massachusetts, Twine Health was developed at the MIT Medical Lab and operates as a subsidiary of Fitbit, Inc. since 2018.

Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.

Klarismo Limited, based in London, specializes in body analysis through advanced 3D body scanning technology. The company provides health-conscious consumers and amateur athletes with a unique service that transforms full-body magnetic resonance imaging (MRI) scans into detailed 3D virtual models. These models offer accurate volumetric measurements of muscle and fat tissues, allowing users to explore and understand their body composition in depth. With annotated information, individuals can learn about different body parts and monitor changes over time, making it easier to assess the effectiveness of their fitness or diet regimens. Klarismo also supports private medical imaging centers by optimizing their asset utilization and contributing to a database of full-body MRI scans for medical research. Founded in 2014, Klarismo is committed to enhancing users' health and fitness insights through innovative technology.

Tempo designs and develops a home fitness platform with personal guidance to help users in their training sessions. It features live elite trainers who can help users when they make mistakes. It has built-in three-dimensional sensors that track form, counts reps, and recommend weights. It helps users to improve in real-time. Powered by 3D motion sensors and AI, it analyzes 25 of the body’s essential joints as users work out and gives understood form feedback. Moawia Eldeeb and Joshua Augustin founded it as Pivot in 2015, with its headquarters in San Francisco in California.

Catalia Health Inc. is a San Francisco-based company that develops a cloud-based patient care management platform aimed at enhancing healthcare delivery. Established in 2014, the company integrates artificial intelligence, psychology, and medicine to improve patient engagement and support. Its platform provides healthcare providers with real-time data on patient progress and challenges, facilitating effective communication through mobile apps, web interfaces, and an interactive robotic coach. By delivering tailored conversations to patients, Catalia Health aims to address ongoing healthcare issues, ultimately enabling healthcare professionals to monitor adherence to treatment and improve overall patient outcomes.

Atomwise, Inc. is a biotechnology company based in San Francisco that specializes in using deep learning artificial intelligence for small molecule drug discovery. Founded in 2012, Atomwise developed the AtomNet platform, which enables virtual screening of molecules by predicting the binding of small molecules to proteins through a statistical approach that leverages experimental affinity measurements and protein structures. The company focuses on addressing over 600 unique disease targets and has established partnerships with more than 250 organizations, including pharmaceutical and biotechnology firms. Atomwise's technology has been recognized for its ability to unlock previously undruggable targets, and the company has raised significant funding to support its mission of accelerating drug discovery and development.

Zebra Medical Vision Ltd. is a company that develops an imaging analytics platform aimed at enhancing patient care in healthcare institutions. Founded in 2014 and based in Shefayim, Israel, the platform utilizes advanced learning and computer vision algorithms to assist clinicians in identifying patients at risk of various diseases. This technology supports healthcare providers in implementing effective risk management and preventative care strategies. Zebra Medical Vision also supplies tools and datasets for machine-learning researchers, facilitating the rapid development of decision support tools and diagnostic solutions. The company has established strategic partnerships with organizations such as USARAD Holdings and TELUS Ventures, and has secured a total of $52 million in funding from notable investors, including Khosla Ventures and Nvidia. Its AI-driven products are FDA cleared and are utilized in hospitals across multiple regions, including the U.S., Europe, Australia, India, and Latin America, positioning Zebra Medical Vision as a leader in the field of medical imaging and analytics.

DB CyberTech specializes in developing predictive data loss prevention technologies that safeguard business data through advanced security measures. The company employs deep protocol extraction, machine learning, and behavioral analysis to non-intrusively assess database infrastructures, allowing for the identification of insider threats and potential database attacks. Its solutions provide clients with comprehensive insights into database activities and application interactions, enhancing situational awareness and security posture. DB CyberTech serves a diverse clientele, including financial institutions, healthcare providers, manufacturers, and government entities. Founded in 2009 and headquartered in San Diego, California, the company was previously known as DB Networks before rebranding in May 2018.